NSPRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
InspireMD, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.44−0.02 (-3.34%)
Close on Oct 19, 2026
- Market cap
- $37.25M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
53.6%
25M of 46M shares
Institutional holders
37
7 new, 5 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
18 buys · 12 sales
Net bought $391.23K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daniel Mack | 4,819,647 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Wilmot B. Harkey | 4,255,729 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Michael A. Lawless | 3,614,731 | 8.60% | 13D (active) | Jun 26, 2025 |
| Aberdeen Group plc | 3,173,364 | 7.49% | 13G (passive) amendment | Dec 31, 2025 |
| Orbimed Advisors LLC | 3,133,405 | 7.40% | 13G (passive) | Dec 31, 2025 |
| Nantahala Capital Management, LLC | 3,037,935 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Marshall Wace, Llp | 28,103,699 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Marvin Slosman | 2,556,760 | 5.18% | 13D (active) | Jan 22, 2026 |
| Parkman Healthcare Partners LLC | 2,440,633 | 5.80% | 13G (passive) | Sep 30, 2025 |
| Nantahala Capital Partners Limited Partnership | 2,418,016 | 5.68% | 13G (passive) amendment | Sep 30, 2025 |
| Venkataraman Balaji | 2,143,698 | 5.10% | 13G (passive) | Jul 30, 2025 |
| Rosalind Advisors, Inc. | 10,987,104 | 9.20% | 13G (passive) amendment | Dec 31, 2025 |
| Salamon Steven A J | 10,987,104 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| Aharon Gil | 10,987,104 | 9.90% | 13G (passive) amendment | Aug 1, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NSPR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6,752,968 | 14.53% | $4.73M | +3,376,484 | 0.08% |
| Rosalind Advisors, Inc. | 3,905,743 | 8.40% | $2.73M | – | 1.02% |
| abrdn plc | 3,698,364 | 7.96% | $2.59M | +525,000 | 0.00% |
| Orbimed Advisors LLC | 3,133,405 | 6.74% | $2.19M | – | 0.04% |
| Parkman Healthcare Partners LLC | 2,416,518 | 5.20% | $1.69M | – | 0.17% |
| Marshall Wace, Llp | 1,860,405 | 4.00% | $1.30M | – | 0.00% |
| Soleus Capital Management, L.P. | 1,045,708 | 2.25% | $732.10K | – | 0.03% |
| Pura Vida Investments, LLC | 450,517 | 0.97% | $315.41K | – | 1.91% |
| Ingalls & Snyder LLC | 368,800 | 0.79% | $258 | −10,500 | 0.01% |
| Affiance Financial, LLC | 250,370 | 0.54% | $175.28K | – | 0.03% |
| Velan Capital Investment Management LP | 148,138 | 0.32% | $103.71K | −1,951,514 | 0.06% |
| BlackRock, Inc. | 122,993 | 0.26% | $86.11K | +42,544 | 0.00% |
| Renaissance Technologies LLC | 112,832 | 0.24% | $78.99K | +95,223 | 0.00% |
| Creative Planning | 108,964 | 0.23% | $76.29K | +89,250 | 0.00% |
| Schonfeld Strategic Advisors LLC | 99,275 | 0.21% | $69.50K | New | 0.00% |
| Hrt Financial LP | 59,754 | 0.13% | $41 | New | 0.00% |
| XTX Topco Ltd | 49,029 | 0.11% | $34.33K | +36,671 | 0.00% |
| Centiva Capital, LP | 44,123 | 0.09% | $30.89K | +19,357 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 40,332 | 0.09% | $28 | New | 0.00% |
| Millennium Management LLC | 37,677 | 0.08% | $26.38K | −74,746 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 37 | 25M | 53.6% | 7 / 11 | 5 / 5 | 4M | 2M |
| Q1 2026 | 35 | 23M | 49.0% | 3 / 4 | 10 / 12 | 0M | 0M |
| Q4 2025 | 45 | 23M | 49.8% | 12 / 7 | 6 / 8 | 2M | 2M |
| Q3 2025 | 41 | 23M | 48.9% | 10 / 15 | 3 / 5 | 9M | 1M |
| Q2 2025 | 36 | 14M | 30.3% | 9 / 9 | 0 / 8 | 1M | 0M |
| Q1 2025 | 35 | 13M | 27.8% | 7 / 4 | 5 / 1 | 1M | 1M |
| Q4 2024 | 30 | 13M | 27.3% | 4 / 5 | 3 / 2 | 1M | 1M |
| Q3 2024 | 28 | 12M | 26.7% | 5 / 2 | 5 / 1 | 0M | 2M |
| Q2 2024 | 24 | 14M | 30.1% | 1 / 3 | 3 / 4 | 4M | 0M |
| Q1 2024 | 27 | 10M | 22.2% | 2 / 3 | 4 / 3 | 0M | 2M |
| Q4 2023 | 28 | 12M | 26.8% | 6 / 7 | 1 / 3 | 4M | 0M |
| Q3 2023 | 25 | 9M | 18.8% | 5 / 5 | 1 / 2 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NSPR | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Micro-Cap ETF | 114,832 | 0.25% | $80.39K | 0.01% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 18,244 | 0.04% | $16.80K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 8,161 | 0.02% | $5.71K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marvin Slosman | CEO and President, Director | 3,556,658 | 7.65% | May 13, 2026 |
| Shane Thomas Gleason | Chief Commercial Officer | 1,053,882 | 2.27% | May 21, 2026 |
| Michael A. Lawless | Chief Financial Officer | 691,695 | 1.49% | Jan 16, 2026 |
| Andrea Tommasoli | Chief Operating Officer | 954,389 | 2.05% | Jan 16, 2026 |
| Craig Shore | CFO and CAO | 1,112,460 | 2.39% | Jan 10, 2025 |
| Patrick Verta | EVP Clinical/Medical Affairs | 311,532 | 0.67% | Jan 10, 2025 |
| Gary S. Roubin | Director | 834,478 | 1.79% | Sep 23, 2026 |
| Michael Berman | Director | 597,580 | 1.29% | Sep 23, 2026 |
| Paul Stuka | Director | 1,091,575 | 2.35% | Sep 23, 2026 |
| Scott R. Ward | Director | 237,096 | 0.51% | May 8, 2026 |
| Raymond W. Cohen | Director | 92,417 | 0.20% | Jan 16, 2026 |
| Danny L. Dearen | Director | 102,047 | 0.22% | Jan 16, 2026 |
| Kathryn Arnold | Director | 303,087 | 0.65% | Dec 31, 2025 |
| Thomas J. Kester | Director | 458,573 | 0.99% | Sep 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul Stuka Director | May 27, 2026 | Buy | +20,000 | $0.88 | $17.60K | 667,871 |
| Shane Thomas Gleason Chief Commercial Officer | May 19, 2026 | Sale | −22,778 | $1.01 | $23.01K | 1,053,882 |
| Paul Stuka Director | May 14, 2026 | Buy | +5,000 | $1.15 | $5.75K | 647,871 |
| Paul Stuka Director | May 13, 2026 | Buy | +10,000 | $1.16 | $11.60K | 642,871 |
| Marvin Slosman CEO and President, Director | May 12, 2026 | Buy | +21,000 | $1.20 | $25.20K | 3,556,658 |
| Paul Stuka Director | May 11, 2026 | Buy | +10,000 | $1.19 | $11.90K | 632,871 |
| Paul Stuka Director | May 11, 2026 | Buy | +10,000 | $1.19 | $11.90K | 632,871 |
| Paul Stuka Director | May 8, 2026 | Buy | +65,626 | $1.16 | $76.13K | 622,871 |
| Paul Stuka Director | May 8, 2026 | Buy | +65,626 | $1.16 | $76.13K | 622,871 |
| Gary S. Roubin Director | May 7, 2026 | Buy | +90,000 | $1.18 | $106.20K | 834,478 |
| Paul Stuka Director | May 7, 2026 | Buy | +6,378 | $1.15 | $7.33K | 531,599 |
| Scott R. Ward Director | May 7, 2026 | Buy | +73,255 | $1.15 | $84.24K | 237,096 |
| Paul Stuka Director | May 6, 2026 | Buy | +1,517 | $1.12 | $1.70K | 525,221 |
| Scott R. Ward Director | May 6, 2026 | Buy | +15,995 | $1.15 | $18.39K | 163,841 |
| Shane Thomas Gleason Chief Commercial Officer | Feb 2, 2026 | Sale | −2,941 | $1.59 | $4.68K | 1,076,660 |
| Shane Thomas Gleason Chief Commercial Officer | Feb 2, 2026 | Sale | −2,000 | $1.60 | $3.20K | 1,139,177 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 30, 2026 | Sale | −2,900 | $1.63 | $4.73K | 1,141,177 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 29, 2026 | Sale | −5,000 | $1.65 | $8.25K | 1,144,077 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 28, 2026 | Sale | −12,395 | $1.65 | $20.45K | 1,149,077 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 27, 2026 | Sale | −4,781 | $1.66 | $7.94K | 1,161,472 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 22, 2026 | Sale | −8,411 | $1.57 | $13.21K | 1,166,253 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 21, 2026 | Sale | −17,593 | $1.62 | $28.50K | 1,174,664 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 20, 2026 | Sale | −2,955 | $1.59 | $4.70K | 1,192,257 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 16, 2026 | Sale | −2,250 | $1.61 | $3.62K | 1,195,212 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 15, 2026 | Sale | −2,909 | $1.58 | $4.60K | 1,197,462 |
| Raymond W. Cohen Director | Jan 14, 2026 | Award | +44,030 | – | – | 92,417 |
| Scott R. Ward Director | Jan 14, 2026 | Award | +88,053 | – | – | 147,846 |
| Paul Stuka Director | Jan 14, 2026 | Award | +132,076 | – | – | 523,704 |
| Marvin Slosman CEO and President, Director | Jan 14, 2026 | Award | +1,114,792 | – | – | 3,535,658 |
| Michael Berman Director | Jan 14, 2026 | Award | +88,053 | – | – | 352,586 |
| Gary S. Roubin Director | Jan 14, 2026 | Award | +88,053 | – | – | 744,478 |
| Andrea Tommasoli Chief Operating Officer | Jan 14, 2026 | Award | +226,695 | – | – | 954,389 |
| Michael A. Lawless Chief Financial Officer | Jan 14, 2026 | Award | +226,695 | – | – | 691,695 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 14, 2026 | Award | +453,390 | – | – | 1,200,371 |
| Danny L. Dearen Director | Jan 14, 2026 | Award | +44,030 | – | – | 102,047 |
| Kathryn Arnold Director | Dec 30, 2025 | Award | +55,556 | – | – | 303,087 |
| Paul Stuka Director | Dec 9, 2025 | Buy | +2,710 | $1.81 | $4.91K | 391,628 |
| Paul Stuka Director | Dec 9, 2025 | Buy | +5,073 | $1.81 | $9.18K | 391,628 |
| Paul Stuka Director | Dec 5, 2025 | Buy | +5,073 | $1.86 | $9.44K | 388,918 |
| Paul Stuka Director | Dec 4, 2025 | Buy | +10,130 | $1.85 | $18.74K | 383,845 |
| Paul Stuka Director | Nov 12, 2025 | Buy | +13,431 | $1.62 | $21.76K | 373,715 |
| Gary S. Roubin Director | Oct 7, 2025 | Award | +48,000 | – | – | 656,425 |
| Thomas J. Kester Director | Sep 15, 2025 | Award | +37,815 | – | – | 458,573 |
| Marvin Slosman CEO and President, Director | Jul 30, 2025 | Buy | +10,330 | $2.42 | $25.00K | 2,420,866 |
| Paul Stuka Director | Jul 30, 2025 | Buy | +20,661 | $2.42 | $50.00K | 444,195 |
| Thomas J. Kester Director | Jul 30, 2025 | Buy | +30,991 | $2.42 | $75.00K | 420,758 |
| Gary S. Roubin Director | Jul 30, 2025 | Buy | +41,322 | $2.42 | $100.00K | 608,425 |
| Thomas J. Kester Director | Jul 11, 2025 | Option exercise | +30,624 | $1.38 | $42.26K | 389,767 |
| Paul Stuka Director | Jul 1, 2025 | Option exercise | +87,500 | $1.38 | $120.75K | 423,534 |
| Michael Berman Director | Jun 29, 2025 | Option exercise | +61,248 | $1.38 | $84.52K | 244,994 |
| Gary S. Roubin Director | Jun 25, 2025 | Option exercise | +30,624 | $1.38 | $42.26K | 567,103 |
| Shane Thomas Gleason Chief Commercial Officer | May 30, 2025 | Sale | −7,186 | $2.51 | $18.04K | 1,079,601 |
| Shane Thomas Gleason Chief Commercial Officer | May 29, 2025 | Sale | −3,760 | $2.51 | $9.44K | 1,086,787 |
| Shane Thomas Gleason Chief Commercial Officer | May 27, 2025 | Sale | −1,572 | $2.51 | $3.95K | 1,090,547 |
| Shane Thomas Gleason Chief Commercial Officer | May 23, 2025 | Sale | −2,482 | $2.51 | $6.23K | 1,092,119 |
| Shane Thomas Gleason Chief Commercial Officer | Feb 25, 2025 | Sale | −10,000 | $3.65 | $36.50K | 1,094,601 |
| Shane Thomas Gleason Chief Commercial Officer | Feb 4, 2025 | Sale | −5,132 | $2.46 | $12.62K | 1,104,601 |
| Shane Thomas Gleason Chief Commercial Officer | Feb 3, 2025 | Sale | −7,073 | $2.51 | $17.75K | 1,109,733 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 31, 2025 | Sale | −9,923 | $2.55 | $25.30K | 1,116,806 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 30, 2025 | Sale | −2,454 | $2.51 | $6.16K | 1,126,729 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.